Cellesce Signs a License Agreement with Hubrecht Organoid Technology (HUB) for the Expansion of Organoids
Shots:
- Cellesce & Hubrecht Organoid Technology (HUB) enters into an agreement for the expansion of breast organoids utilizing bioprocessing technology and HUB’s Organoid Technology at large scale
- The focus of the agreement is to develop genetically and phenotypically stable breast cancer organoids which retains the characteristics of tumors for drug discovery programmes
- HUB’s Organoid Technology is a drug-screening technology based on LGR5+ intestinal stem cells forming polarized epithelium for pre-clinical drug discovery and validation enabling generation of in-vitro models
Click here Ref: Cellesce | Image: Twitter
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com